Navigation Links
CryoLife Posts Record Annual Revenues of $116.6 Million
Date:2/17/2011

ny does not believe that it will be able to distribute.  Excluding these charges, adjusted net income for the full year of 2010 was $9.5 million, or $0.34 per basic and fully diluted common share.

The Company recorded pretax charges in the full year of 2010 of approximately $1.4 million in costs related to litigation with Medafor, approximately $1.0 million related to business development activities, and $729,000 related to the write-off of capitalized legal expenses associated with BioGlue® Surgical Adhesive intellectual property rights in Germany.  Additionally, the Company recorded a $1.3 million gain on valuation of the derivative related to the investment in Medafor common stock.

Preservation service revenues for the fourth quarter of 2010 increased 2 percent to $14.0 million compared to $13.8 million for the fourth quarter of 2009.  Preservation service revenues for the full year of 2010 increased 6 percent to $59.7 million compared to $56.5 million for the full year of 2009.  The increase in preservation service revenues for the fourth quarter of 2010 was primarily due to increased shipments of cardiac tissues.  The increase in preservation service revenues for the full year of 2010 was primarily due to increased shipments of cardiac and vascular tissues.  

Product revenues, which consist primarily of sales of BioGlue, HemoStase, and PerClot, were $15.1 million for the fourth quarter of 2010 compared to $14.5 million for the fourth quarter of 2009, an increase of 4 percent.  Product revenues were $56.4 million for the full year of 2010 compared to $54.2 million for the full year of 2009, an increase of 4 percent.  The increase in product revenues was primarily due to an increase in HemoStase revenues and, to a lesser extent, the addition of PerClot revenues in the fourth quarter of 2010.

Total gross margins were 60 percent and 61 percent for the fourth quarters of 2010 and 2009, respecti
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. CryoLife Announces Release Date and Teleconference Call Details for 2010 Fourth Quarter and Year End Financial Results
2. CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference
3. CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe
4. CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
5. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
6. CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
7. CryoLife Provides Initial 2010 Financial Guidance
8. CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference
9. CryoLife to Present at Upcoming Investor Conferences in New York
10. CryoLife Reports Record Quarterly Revenues of $28.2 Million
11. CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative biopharmaceutical ... present at the Barclays Global Healthcare Conference ... Miami Beach Hotel in Miami , ... M.D., President and Chief Executive Officer of Aratana Therapeutics, ...
(Date:3/4/2015)... 4, 2015  Bayer HealthCare today announced that ... accepted the company,s Biologics License Application (BLA) for ... is seeking FDA approval of the investigational compound, ... hemophilia A in children and adults. ... therapies to hemophilia A patients who need them," ...
(Date:3/4/2015)... -- Halyard Health, Inc. (NYSE: HYH ) today ... and related key planning assumptions. "This is ... our fourth quarter results, our first as an independent ... a smooth separation from Kimberly-Clark and I,m pleased with ... growth and margin improvement in the fourth quarter while ...
Breaking Medicine Technology:Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 2Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 4Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 5Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 6Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 7Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 8Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 9Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 10Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 11Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 12Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 13Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 14Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 15Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 16Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 17Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 18Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 19Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 20Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 21Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 22Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 23Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 24Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 25Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 26Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 27Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 28Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 29Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 30Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 31
... LAKE FOREST, Ill., March 5, 2012  RoundTable Healthcare ... exclusively on the healthcare industry, announced today that ... the newly formed RoundTable III Platform Development Corporation ... Mr. Davies will focus his attention on the ...
... 5, 2012   Synteract , Inc., a full-service contract research ... as senior vice president of sales and marketing and has ... global project management, to support growth in the company and ... COO Stewart Bieler, and CFO Patrik Jeanmonod on the executive ...
Cached Medicine Technology:RoundTable Healthcare Partners Names Kent J. Davies CEO of Newly Formed Platform Development Corporation 2Synteract Expands Executive Roles to Support Growth 2Synteract Expands Executive Roles to Support Growth 3
(Date:3/4/2015)... PA (PRWEB) March 04, 2015 Cook ... non-profit organization that teaches healthy cooking to people touched ... AstraZeneca Hope Lodge. The program, run by founder Ann ... Hospitality and Sport Management. The unique partnership will expand ... Ann Ogden founded CFYL in 2007. After going through ...
(Date:3/4/2015)... More than a year after announcing ... with low testosterone treatments ( http://www.testosteronelawsuithub.com/ ), the U.S. ... now require manufacturers to warn patients that this class ... and strokes. In a Drug Safety Communication ... it was requiring testosterone manufacturers to update the drugs’ ...
(Date:3/4/2015)... Optrix by Body Glove ” was featured on NewsWatch ... a look at the latest and coolest technology products ... reporter for NewsWatch and a technology expert, conducted the ... an ultra-rugged, waterproof case with an interchangeable lens system. ... the Consumer Electronics Show in Las Vegas every year. ...
(Date:3/4/2015)... The popular all-natural supplement brand, Liporidex ... Program. The customized program provides a tailored diet and ... and fitness levels to follow and achieve their weight ... , “We’re really proud to announce our new program ... winning techniques to help people according to their specific ...
(Date:3/4/2015)... Information Innovators Inc . (Triple-i) is honored ... the company as Chief Technology Officer. Mr. Dvorak will ... company, including customer-centric strategies and initiatives, and promoting continuous ... as a technology executive and visionary. Prior to joining ... including oversight of enterprise data management, analytic software development, ...
Breaking Medicine News(10 mins):Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:A Waterproof Phone Case with an Interchangeable Lens System was Featured on NewsWatch Television on January 30, 2015 2Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 3
... 7 (HealthDay News) -- In November, the U.S. Food and ... the treatment of breast cancer. But, a new study ... with a specific type of aggressive breast tumor when used ... (bevacizumab) had been approved in the United States in 2008 ...
... the fierce national debate over a new federal law ... widely assumed that private health insurance can do a ... U.S. government. But a first-of-its-kind analysis of newly ... comes to infants covered by insurance. Among the ...
... HealthDay Reporter , WEDNESDAY, Dec. 7 (HealthDay News) ... with low-risk prostate cancer, a new draft report released ... concluded that research on the safety of "active surveillance" ... men opt for surgery or other treatments that can ...
... have altered natural bioelectrical communication among cells to directly ... at a particular location within a vertebrate organism. Using ... biologists at Tufts University,s School of Arts and Sciences ... of the head area. The researchers achieved most ...
... California,s low-income seniors with disabilities are struggling to remain in ... and may be slashed even further, according to a new ... with support from The SCAN Foundation. Should ... to In-Home Supportive Services (IHSS) on Dec. 15, as proposed ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Dec. 7 ... through strategically placed "seeds" had double the risk of a ... their entire breast, new research finds. This type ... side effects, including infection, according to the study. "We ...
Cached Medicine News:Health News:Avastin Boosted Survival for Type of Aggressive Breast Cancer: Study 2Health News:Public health insurance offers insured infants better, less costly care than private plans 2Health News:Public health insurance offers insured infants better, less costly care than private plans 3Health News:Public health insurance offers insured infants better, less costly care than private plans 4Health News:Public health insurance offers insured infants better, less costly care than private plans 5Health News:Active Surveillance May Benefit Men With Low-Risk Prostate Cancer 2Health News:Researchers discover that changes in bioelectric signals cause tadpoles to grow eyes in back, tail 2Health News:Researchers discover that changes in bioelectric signals cause tadpoles to grow eyes in back, tail 3Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 2Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 3Health News:Older Californians with disabilities struggle to remain at home as public programs lose funding 4Health News:Targeted Radiation May Not Be Better for Breast Cancer 2Health News:Targeted Radiation May Not Be Better for Breast Cancer 3
... stents that save inventory, shelf space, and ... lengths from 22 cm to 28 cm. ... to glide over any guidewire and through ... ease of placement and patient comfort in ...
... internal drainage from the ureteropelvic junction to ... for ease of placement and patient compliance. ... for repositioning and ease of removal. AQ® ... that when activated, attracts and holds water ...
The CMV IgM enzyme immunoassay is for the qualitative detection of antibodies to cytomegalovirus. The CMV IgM assay is primarily indicated for the detection of early or recent infection....
The Shandon Sequenza uses the Shandon Coverplate system which ensures consistency and excellent staining quality. , , ,Allows the user to perform large immunostaining runs (up to 50 slides/run...
Medicine Products: